Literature DB >> 19388151

Neuromuscular hip dysplasia in Charcot-Marie-Tooth disease type 1A.

Nigel S Bamford1, Klane K White, Stephanie A Robinett, Randolph K Otto, Sidney M Gospe.   

Abstract

Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders, affecting 36 in 100,000 people. CMT type 1A (hereditary motor and sensory neuropathy) is the most frequent form of this disease, affecting 60 to 80% of the CMT population, but its diagnosis may be delayed because of inconsistent clinical signs and symptoms and a considerable variability in age at onset. Here, we report on four children (aged 10-17y) who presented with neuromuscular hip dysplasia and other orthopedic abnormalities but were only later diagnosed with CMT 1A. Hip dysplasia may be the initial clinical sign in CMT, so children with late-manifesting hip disease (i.e. age >8y) should be examined for signs of peripheral neuropathy, particularly when presenting with a 'waddling' or broad-based gait.

Entities:  

Mesh:

Year:  2009        PMID: 19388151     DOI: 10.1111/j.1469-8749.2008.03234.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  3 in total

1.  Hip dysplasia is more severe in Charcot-Marie-Tooth disease than in developmental dysplasia of the hip.

Authors:  Eduardo N Novais; Sara D Bixby; John Rennick; Patrick M Carry; Young-Jo Kim; Michael B Millis
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

2.  Whole exome sequencing revealed a novel dystrophin-related protein-2 (DRP2) deletion in an Iranian family with symptoms of polyneuropathy.

Authors:  Maryam Tahmasebi-Birgani; Mohammadreza Hajjari; Neda Golchin; Bita Shalbafan; Javad Mohammadi-Asl; Forouzan Sadeghian
Journal:  Iran J Basic Med Sci       Date:  2019-05       Impact factor: 2.699

3.  Hip dysplasia associated with a hereditary sensorimotor polyneuropathy mimics a myopathic process.

Authors:  Mohammad Javad Hadianfard; Alireza Ashraf
Journal:  Ann Indian Acad Neurol       Date:  2012-07       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.